Mark A. Kay
Impact in
- Genetics top 0.01%
- Virus-based gene therapy research
- Molecular Biology top 0.05%
- RNA Interference and Gene Delivery
- CRISPR and Genetic Engineering
- Viral Infectious Diseases and Gene Expression in Insects
- Advanced biosensing and bioanalysis techniques
Papers in
-
- RNA Interference and Gene Delivery 100
- CRISPR and Genetic Engineering 97
- Viral Infectious Diseases and Gene Expression in Insects 43
- RNA Research and Splicing 24
- Genetics 190
- Virus-based gene therapy research 181
- Co-authors
- Anja Ehrhardt (16 shared papers)Dirk Grimm (24 shared papers)Theresa A. Storm (27 shared papers)Leonard Meuse (31 shared papers)Clare E. Thomas (4 shared papers)Hiroyuki Nakai (22 shared papers)Stephen R. Yant (21 shared papers)Luigi Naldini (3 shared papers)
- Journals
- Molecular Therapy (51 papers)Human Gene Therapy (28 papers)Journal of Virology (26 papers)Blood (12 papers)Proceedings of the National Academy of Sciences (10 papers)
- Partner nations
- United StatesGermanyItaly
In The Last Decade
Mark A. Kay
293 papers receiving 32.7k citations
Mark A. Kay's Hit Papers
Peers
Comparison fields: 5 of 158
- Genetics 16.5k
- Molecular Biology 24.2k
- Hepatology 1.9k
- Cancer Research 2.9k
- Oncology 4.0k
Countries citing papers authored by Mark A. Kay
This map shows the geographic impact of Mark A. Kay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Kay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Kay more than expected).
Fields of papers citing papers by Mark A. Kay
This network shows the impact of papers produced by Mark A. Kay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Kay. The network helps show where Mark A. Kay may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark A. Kay, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 298 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Progress and problems with the use of viral vectors for gene therapy Hit paper breakdown → | 2003 | 1980 |
| 2 | Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways Hit paper breakdown → | 2006 | 1299 |
| 3 | Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics Hit paper breakdown → | 2001 | 1003 |
| 4 | RNA interference in adult mice Hit paper breakdown → | 2002 | 853 |
| 5 | Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector Hit paper breakdown → | 2000 | 780 |
| 6 | Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice Hit paper breakdown → | 2007 | 606 |
| 7 | AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B Hit paper breakdown → | 2003 | 583 |
| 8 | Human tRNA-derived small RNAs in the global regulation of RNA silencing Hit paper breakdown → | 2010 | 581 |
| 9 | In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses Hit paper breakdown → | 2008 | 542 |
| 10 | A nonviral minicircle vector for deriving human iPS cells Hit paper breakdown → | 2010 | 539 |
| 11 | State-of-the-art gene-based therapies: the road ahead Hit paper breakdown → | 2011 | 525 |
| 12 | Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors Hit paper breakdown → | 1997 | 504 |
| 13 | 2006 | 480 | |
| 14 | 2004 | 454 | |
| 15 | A transfer-RNA-derived small RNA regulates ribosome biogenesis Hit paper breakdown → | 2017 | 420 |
| 16 | 2000 | 417 | |
| 17 | 2003 | 388 | |
| 18 | 2001 | 371 | |
| 19 | 2009 | 361 | |
| 20 | 1997 | 354 |
About Mark A. Kay
Mark A. Kay is a scholar working on Molecular Biology, Genetics, Infectious Diseases, Oncology and Hepatology, having authored 298 papers that have together received 33.6k indexed citations. Recurring topics across this work include Virus-based gene therapy research (181 papers), RNA Interference and Gene Delivery (100 papers), CRISPR and Genetic Engineering (97 papers), Viral Infectious Diseases and Gene Expression in Insects (43 papers), Viral gastroenteritis research and epidemiology (28 papers), CAR-T cell therapy research (27 papers), RNA Research and Splicing (24 papers) and Liver physiology and pathology (23 papers). The work is most often cited by research in Genetics (16.5k citations), Molecular Biology (24.2k citations), Hepatology (1.9k citations), Cancer Research (2.9k citations) and Oncology (4.0k citations). Mark A. Kay has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Anja Ehrhardt, Dirk Grimm, Theresa A. Storm, Leonard Meuse, Clare E. Thomas, Hiroyuki Nakai, Stephen R. Yant, Luigi Naldini, André Lieber and Joseph C. Glorioso. Their work appears in journals such as Molecular Therapy, Human Gene Therapy, Journal of Virology, Blood and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.